Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Tyra Bioscience ( (TYRA) ) is now available.
On August 21, 2025, Tyra Biosciences announced the dosing of the first child in the BEACH301 Phase 2 clinical study of dabogratinib for achondroplasia. Initial safety results from this study are expected in the second half of 2026, potentially impacting the company’s operations and positioning in the biotechnology sector.
The most recent analyst rating on (TYRA) stock is a Buy with a $33.00 price target. To see the full list of analyst forecasts on Tyra Bioscience stock, see the TYRA Stock Forecast page.
Spark’s Take on TYRA Stock
According to Spark, TipRanks’ AI Analyst, TYRA is a Neutral.
Tyra Bioscience’s overall stock score reflects its high-risk profile typical for early-stage biotechnology firms. While the company demonstrates strong liquidity, its lack of revenue and increasing operational losses highlight financial challenges. Technical indicators show positive momentum, but the high valuation risk due to negative earnings limits the score. Investors should be cautious, considering both the potential for significant growth and the inherent risks.
To see Spark’s full report on TYRA stock, click here.
More about Tyra Bioscience
Tyra Biosciences, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for genetic disorders. The company’s primary product in this context is dabogratinib, aimed at treating achondroplasia.
Average Trading Volume: 301,142
Technical Sentiment Signal: Sell
Current Market Cap: $543.6M
For a thorough assessment of TYRA stock, go to TipRanks’ Stock Analysis page.